WO2015035778A1 - 苯并吡喃化合物的制备方法和抗肺纤维化的用途 - Google Patents
苯并吡喃化合物的制备方法和抗肺纤维化的用途 Download PDFInfo
- Publication number
- WO2015035778A1 WO2015035778A1 PCT/CN2014/075773 CN2014075773W WO2015035778A1 WO 2015035778 A1 WO2015035778 A1 WO 2015035778A1 CN 2014075773 W CN2014075773 W CN 2014075773W WO 2015035778 A1 WO2015035778 A1 WO 2015035778A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- benzopyran
- benzopyran compound
- hydrogen
- methanol
- Prior art date
Links
- -1 benzopyran compound Chemical class 0.000 title claims abstract description 38
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 15
- 239000001257 hydrogen Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 12
- 241000667462 Streptomyces xiamenensis Species 0.000 claims abstract description 10
- 238000000855 fermentation Methods 0.000 claims abstract description 10
- 230000004151 fermentation Effects 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 5
- 238000000746 purification Methods 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 9
- 150000001562 benzopyrans Chemical class 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 6
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007791 liquid phase Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 241000187747 Streptomyces Species 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000009798 acute exacerbation Effects 0.000 claims description 2
- 201000004073 acute interstitial pneumonia Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000010898 silica gel chromatography Methods 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 abstract description 10
- 210000004072 lung Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 229940125904 compound 1 Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 5
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 3
- 230000003510 anti-fibrotic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 2
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000002044 Rhizophora apiculata Species 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Definitions
- the invention belongs to the field of natural medicinal chemistry, and particularly relates to a preparation method of a benzopyran compound and a use for anti-pulmonary fibrosis.
- benzopyran benzopyran compound namely, Xiamenmycin, such as Japanese special U [Kawamura, N.; Tsuj i, E.; Watanabe, Y.; Tsuchihashi, K.; Takako , T. Benzopyran derivatives, their manufacture with Streptomyces species, and their use for treatment of asthma and rheumatoid arthritis. Dai ichi Seiyaku Co. , Ltd.; Mercian Corp.: Kyoto, Japan, 7 March 2000.
- the genetically engineered strain CGMCC No. 5675 is Streptomyces xiamenensis carrying rifamycin and streptomycin resistance, and no literature reports on the isolation of benzopyrans from this strain have been reported. Since Xiamenmycin C (common name of the benzopyran compound of the present invention) loses the amino acid side chain compared to the Xiamenmycin itself, it is a novel structural compound. For the first time, the anti-pulmonary fibrosis activity of the compound was measured and found to be superior to the known compound Xiamenmycin. Summary of the invention
- the invention first discovered genetic engineering
- the benzopyran compound can be produced in the extract of the strain - Streptomyces xiamenensis) CGMCC No. 5675.
- the Streptomyces sinensis iStreptomyces xiamenensis was deposited on December 29, 2011 with the CGMCC China Microbial Culture Collection Management Committee General Microbiology Center. The deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, China. Institute of Microbiology, Chinese Academy of Sciences , The strain collection number is CGMCC No. 5675.
- the present invention relates to a benzopyran compound having the formula: (I):
- R1 is selected from the group consisting of hydrogen, C1 ⁇ C4 fluorenyl, one of the remaining groups after removal of the amino moiety from various amino acids
- R2 is selected from hydrogen, C1 ⁇ C4 thiol, and various amino acids are removed from the amino moiety.
- One of the remaining groups, R3 is selected from hydrogen, one of C1 to C4 fluorenyl groups, and n is any integer from 1 to 4.
- R1 is selected from hydrogen or methyl
- R2 is selected from hydrogen or methyl
- R3 is selected from hydrogen or methyl
- n 1 or 2.
- the structural formula of the benzopyran compound is as shown in the following formula ( ⁇ ):
- the present invention relates to a method for preparing the above benzopyran compound, which is obtained by extracting, separating and purifying a fermentation broth of Strep tomyces xiamenensis CGMCC No. 5675 to obtain the benzopyran. Compound.
- the method specifically includes the following steps:
- the Streptomyces xiamenensis CGMCC No. 5675 is subjected to liquid fermentation culture, and the fermentation broth is extracted and concentrated to obtain a total extract;
- the total extract is eluted by a silica gel column chromatography gradient; the volume ratio of the chloroform to methanol used in the gradient elution is 100:1, 70:1, 60: 1, 50:1, 30:1, 15:1, 10:1, 5:1, 2:1, 1:1; the flow rate is 15 seconds/drop, and each elution fraction receives 200 ml;
- the fraction of the eluted chloroform to methanol in the step B is 15:1, and the gel fraction is eluted by a gel column, and the flow rate is 70 ⁇ 90 sec/drop, and purified. That is, the benzopyran compound is obtained.
- step C further comprises: arranging adjacent groups of the eluted components having a volume ratio of chloroform to methanol of 15:1 Performing high performance liquid chromatography analysis, combining the ultraviolet absorption at 206 nm and 260 nm of the benzopyran compound, and combining the components having the same absorption; the combined components are further purified to obtain the benzopyran Compound.
- the extraction is specifically: after the fermentation liquid is centrifuged, the supernatant is extracted with ethyl acetate, and the residue is extracted with an equal volume of the mixed solvent, and the extract of the supernatant and the extract of the residue are combined.
- the mixed solvent is a mixture of ethyl acetate, methanol, and formic acid in a volume ratio of 80:15:5.
- the purification is specifically: collecting the eluted components, purifying with a high-performance liquid phase, using an acetonitrile/water solution as a mobile phase, and eluting a gradient of acetonitrile to water in a volume ratio of 35 minutes. Within 45: 55 becomes 55: 45.
- the present invention also relates to the use of the aforementioned benzopyran compound for the preparation of an anti-pulmonary fibrosis drug.
- the anti-pulmonary fibrosis drug is for the treatment of acute respiratory distress syndrome, acute interstitial pneumonia or acute exacerbation of chronic idiopathic pulmonary fibrosis.
- the present invention relates to an anti-pulmonary fibrosis pharmaceutical composition
- an anti-pulmonary fibrosis pharmaceutical composition comprising the aforementioned benzopyran compound, or a pharmaceutically acceptable acid or base salt thereof, or a solvent compound as an active ingredient.
- the pharmaceutical composition is an oral preparation or an injection preparation.
- the present invention is a benzopyran compound obtained from an extract of a genetically engineered strain, Streptomyces xiaensis genus CGMCC No. 5675, and the pharmaceutical composition is natural;
- the benzopyran compound of the present invention has the function of inhibiting proliferation and viability of normal human lung fibroblasts, and the effective concentration of anti-fibrotic activity is as high as 15 g/ml, and the toxicity is low;
- Figure 1 is a structural diagram of the benzopyran compound - Xiamenmycin C of the present invention
- Fig. 2 is a quantitative diagram showing the staining of CCK-8 reagent in the proliferation test of benzopyran compound-Xiamycinmycin C in human lung fibroblasts.
- Figure 3 is a quantitative diagram showing the staining of CCK-8 reagent in the inhibition of human lung fibroblast proliferation by Xiamenmycin. detailed description
- the total extract was dissolved in an appropriate amount of chloroform-methanol mixed solvent, and then 10 g of 200-300 mesh silica gel G (Qingdao Ocean Chemical Group Co., Ltd.) was added and mixed, and loaded onto a 50 g normal phase silica gel glass column, with chloroform.
- the fractions with a chloroform-methanol volume ratio of 15:1 were separated by gel column chromatography using S-printed hadex LH-20 as a filler and methanol as an eluent at a flow rate of 70-90 sec/drop, 5 ⁇ 6 ml/tube receiving, combining the obtained components, using high-performance liquid phase separation, using acetonitrile/water solution as mobile phase, eluting gradient of 45% acetonitrile-water solution into 55% acetonitrile-water solution in 35 minutes (volume ratio), using a semi-prepared C18 column to give compound 1.
- the remaining components except the chloroform-methanol volume ratio of 15:1 were analyzed by high performance liquid chromatography.
- the components having the same absorption were combined with the ultraviolet absorption of the compound at 206 nm and 260 nm.
- the combined components were also purified by high-performance liquid phase using an acetonitrile/water solution as an eluent, and the elution gradient of 45% acetonitrile-water solution became 55% acetonitrile-water solution (volume ratio) in 35 minutes.
- this step is a key step.
- the signal of Table 1 is based on the DEPT, 3 ⁇ 4-3 ⁇ 4 COSY, HMQC and HMBC map analysis results. More carbon signals The DEPT method was used to determine and use C (single peak), CH (doublet), CH 2 (triplet) and CH 3 (quadruple).
- Example 2 Inhibition of proliferation and viability of human lung fibroblasts by benzopyran compounds
- Compound 1 (Xiamenmycin C), Compound 2 (Xiamenmycin) Among them, Compound 1 was used as the drug treatment experimental group, and Compound 2 was used as the drug treatment comparison group.
- the final concentration of the compound 1 in the drug treatment experimental group was 15 g/ml, the concentration of the solvent DMS0 was 1/1000, and the control group was DMS0, and the final concentration was 1/1000.
- the drug treatment comparison group compound 2 had a final concentration of 30 ⁇ ⁇ / ⁇ 1 , the solvent DMS0 concentration was 1/1000, and the control group was DMS0, and the final concentration was 1/1000.
- Cell viability was measured after dosing for 0, 1, 2, 3, 4, 5, and 6 days.
- the method is as follows: aspirate the medium, add 100 ⁇ of complete medium and 10 ⁇ l of CCK-8 reagent per well, and incubate for 60 minutes in the incubator to measure the light absorption value at a wavelength of 450 nm. The experiment was repeated three times.
- Fig. 2 The experimental results are shown in Fig. 2. It can be seen from the drawings that Compound 1 can inhibit the proliferation of human lung fibroblasts.
- the administration group showed a significant difference compared with the control group after one day of administration, and the inhibition rate reached 13.8%. After six days of administration, the inhibition rate was 38%. Therefore, the benzopyran compound of the present invention can be used for the preparation of an anti-pulmonary fibrosis drug.
- the effective concentration of Compound 1 was doubled, and the inhibition rate was increased by nearly 10% compared with Compound 2, so the activity was much better than that of the known compound.
- both Compound 1 and Xiamenmycin were characterized by low toxicity. It is a difficult problem in the art to change the structure of the side chain to increase the activity of the compound 1 and the toxicity is relatively low. According to the results of the activity test of the compound 1, it is known to those skilled in the art that the compound produced by modifying the amino group of the compound 1 and the compound formed by the extension of the carbon chain represented by n (SP: the compound defined by the weight 1) are also inevitably quite active. .
- Fig. 3 The experimental results of the comparative group are shown in Fig. 3. It can be seen from the drawings that the compound 2 can inhibit the proliferation of human lung fibroblasts. However, the dose was 30 g/ml, and after one day of administration, the administration group had a significant difference in inhibition rate of 10% compared with the control group. After six days of administration, the inhibition rate was 28.5%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/904,695 US10017489B2 (en) | 2013-09-13 | 2014-04-21 | Method for preparing benzopyran compound and application thereof in treating pulmonary fibrosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310419778.1A CN103508993B (zh) | 2013-09-13 | 2013-09-13 | 苯并吡喃化合物的制备方法和抗肺纤维化的用途 |
CN201310419778.1 | 2013-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015035778A1 true WO2015035778A1 (zh) | 2015-03-19 |
Family
ID=49892474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/075773 WO2015035778A1 (zh) | 2013-09-13 | 2014-04-21 | 苯并吡喃化合物的制备方法和抗肺纤维化的用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10017489B2 (zh) |
CN (1) | CN103508993B (zh) |
WO (1) | WO2015035778A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103740734B (zh) * | 2013-07-01 | 2015-10-14 | 上海交通大学 | 厦门霉素生物合成基因簇、用途及菌株 |
CN103508993B (zh) * | 2013-09-13 | 2015-10-14 | 上海交通大学 | 苯并吡喃化合物的制备方法和抗肺纤维化的用途 |
CN104407084B (zh) * | 2014-11-28 | 2016-03-02 | 上海交通大学 | 血浆中厦门霉素的定量检测以及其代谢物的定性检测方法 |
CN108865961B (zh) * | 2018-06-05 | 2020-07-14 | 上海交通大学 | 一种利用大肠杆菌合成3-香叶草基-4-羟基苯甲酸和厦门霉素的方法 |
CN112940999B (zh) * | 2019-12-11 | 2022-08-23 | 上海交通大学 | 一种厦门链霉菌及其生物合成苯并吡喃类和4-氢喹啉类化合物的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000072766A (ja) * | 1998-08-27 | 2000-03-07 | Dai Ichi Seiyaku Co Ltd | ベンゾピラン誘導体 |
CN102533892A (zh) * | 2010-08-24 | 2012-07-04 | 青海康普生物科技股份有限公司 | 一种生物转化沙棘叶黄酮制备高活性苯并吡喃-4-酮的方法 |
CN102764253A (zh) * | 2012-07-16 | 2012-11-07 | 上海交通大学 | 苯并吡喃生物碱的应用 |
CN103508993A (zh) * | 2013-09-13 | 2014-01-15 | 上海交通大学 | 苯并吡喃化合物的制备方法和抗肺纤维化的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101838622A (zh) * | 2009-08-17 | 2010-09-22 | 国家海洋局第三海洋研究所 | 一种希瓦氏菌及其在微生物燃料电池中的应用 |
-
2013
- 2013-09-13 CN CN201310419778.1A patent/CN103508993B/zh active Active
-
2014
- 2014-04-21 US US14/904,695 patent/US10017489B2/en active Active
- 2014-04-21 WO PCT/CN2014/075773 patent/WO2015035778A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000072766A (ja) * | 1998-08-27 | 2000-03-07 | Dai Ichi Seiyaku Co Ltd | ベンゾピラン誘導体 |
CN102533892A (zh) * | 2010-08-24 | 2012-07-04 | 青海康普生物科技股份有限公司 | 一种生物转化沙棘叶黄酮制备高活性苯并吡喃-4-酮的方法 |
CN102764253A (zh) * | 2012-07-16 | 2012-11-07 | 上海交通大学 | 苯并吡喃生物碱的应用 |
CN103508993A (zh) * | 2013-09-13 | 2014-01-15 | 上海交通大学 | 苯并吡喃化合物的制备方法和抗肺纤维化的用途 |
Non-Patent Citations (1)
Title |
---|
XU, MINJUAN ET AL.: "Identification and Characterization of an Anti-fibrotic Benzopyran Compound Isolated from Mangrove-derived Streptomyces Xiamenensis", MARINE DRUGS, vol. 31, no. 10, 31 October 2012 (2012-10-31), pages 639 - 654 * |
Also Published As
Publication number | Publication date |
---|---|
US10017489B2 (en) | 2018-07-10 |
CN103508993A (zh) | 2014-01-15 |
US20160185742A1 (en) | 2016-06-30 |
CN103508993B (zh) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6531505B2 (en) | Immunosuppressive agents | |
WO2015035778A1 (zh) | 苯并吡喃化合物的制备方法和抗肺纤维化的用途 | |
WO2011032491A1 (zh) | 含迷迭香酸的夏枯草提取物及其制备方法和其在制备防治癌症术后转移的药物中的应用 | |
US6372756B1 (en) | Epimorphian compound and its use | |
WO2017107897A1 (zh) | 一种吲哚生物碱类化合物及其制备方法和用途 | |
CN110483552B (zh) | 一种单萜吲哚生物碱类化合物及其制备方法与应用 | |
CN110257255B (zh) | 红树尖瓣海莲内生真菌来源的苯并吡喃酮衍生物及其制备方法与应用 | |
CN109134574B (zh) | 甾体化合物及其制备方法与应用和抗肿瘤的药物 | |
CN110746421B (zh) | 吲哚单萜类化合物的提取方法及应用 | |
WO2023236797A1 (zh) | Hangtaimycin衍生物及其制备方法和应用 | |
CN111253247B (zh) | 一种具有抗炎活性的新酚酸类化合物的制备方法及应用 | |
CN106831384B (zh) | 一种杜松烷型倍半萜化合物及其制备方法与应用 | |
WO2015066960A1 (zh) | 一种新的链霉倍半萜三醇a及其制备方法和应用 | |
CN110105210B (zh) | 百里酚衍生物及其制备方法和应用 | |
CN109020991B (zh) | 一类美达霉素类化合物及其制备方法和应用 | |
CN113061124B (zh) | 倍半萜二聚体化合物及其制备方法、应用和药物组合物 | |
KR101745504B1 (ko) | 잠분으로부터 항암 활성을 갖는 보미폴리올 및 스티그마스테롤을 분리하는 방법 | |
WO2023240679A1 (zh) | 一对具有抗炎活性的聚酮类化合物及其制备方法和应用 | |
JP6130248B2 (ja) | 新規化合物キノフラシン類、その製造方法、及びその用途、並びに新規微生物 | |
JP4373510B2 (ja) | 18β,19β−ジアセチルオキシ−18α,19α−エポキシ−3,13(16),14−クレロダトリエン−2−オン(エスクレンチンA)および18β,19β−ジアセチルオキシ−18α,19α−エポキシ−3,12,14−クレロダトリエン−2β−イソバレリルオキシ−6β,7α−ジオール(エスクレンチンB)、それらの製法ならびに医薬の製造におけるそれらの使用 | |
CN111704546A (zh) | 一种含氧环己烷衍生物及其制备方法与应用 | |
US20130123204A1 (en) | Method for treating hepatitis b | |
CN114853712B (zh) | 一种色烷型或色烯型杂萜类化合物及其提取方法和应用 | |
CN111808155B (zh) | 树参香豆素类化合物及其在药物中的应用 | |
CN114805465B (zh) | 三萜类化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14844303 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14904695 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 21/07/2016) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14844303 Country of ref document: EP Kind code of ref document: A1 |